Bill Ackman once fled Netflix at a loss, so his decision to buy back in now raises a pointed question: does he see a genuine turnaround forming in a stock that has badly lagged…
Six catalysts are pushing Tesla shares higher after a brutal stretch, but a glaring profitability problem lurking beneath the momentum could stop any rally cold before it starts.
Tesla's stock has bounced, but beneath the rally sit three structural problems that a rising share price cannot fix. Here is what the numbers actually say about where the company is headed.
Apnimed just went public with a single pill designed to replace the CPAP masks that millions of sleep apnea patients abandon every year, but its own FDA filing reveals some uncomfortable truths about how…
Coach handbags are flying off shelves, margins are expanding, and Tapestry just topped earnings estimates, yet the stock cratered 16% in a single session. Whether that brutal selloff signals a buying opportunity or a…
Jim Cramer cheered Brinker International's 21-quarter winning streak on Mad Money, and the stock jumped anyway despite a missed earnings print. But a closer look at the filing reveals a hidden drag that the…
Bill Ackman just made his boldest portfolio move in years, adding Mastercard to his biggest funds at a moment when the stock is quietly losing ground to the broader market. Whether that gap makes…
A California biotech just raised $350 million promising to out-perform opioids without the addiction risk, and its auditors were still warning about survival just months ago. Here is what the science and the filings…
Wave Life Sciences has lost nearly 70% of its value this year, yet its RNA platform spans obesity, rare liver disease, and genetic disorders in ways that could make it irresistible to the right…
Beyond Meat just approved a 1-for-30 reverse split to dodge a Nasdaq delisting notice, but history has a blunt verdict for companies that pull this particular lever at this ratio. The real question is…
Nokia stock has surged nearly 150% over the past year on the promise of AI-powered 6G, and now Nvidia and T-Mobile are putting that promise to a real-world test. What the trial results could…
RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math on who…
Airbnb just punched through its 52-week high after a stunning one-month surge, leaving retirement investors to wrestle with one of the trickiest calls in investing: step in now or stay on the sidelines while…
Wall Street is fixated on SpaceX's lockup expiration while analysts quietly model a software business inside the company that could dwarf Google Cloud by 2030. Here is why the market may be pricing the…
AppLovin has shed more than half its value this year while Wall Street analysts refuse to budge on their bullish targets, creating a tension that forces investors to pick a side: broken growth story…
BioCryst just turned profitable, its HAE drug Orladeyo is minting cash, and a rival's blockbuster acquisition just put the whole rare-disease sector in play. So which pharma giant has the most to lose by…
Wall Street analysts are nearly unanimous in their bullishness on Bank of America even as the stock presses record territory, yet retail investors have largely sat out the entire run. The reason for that…
Cisco and Coherent both report earnings the same afternoon, putting two very different AI networking bets head to head. One carries a 93% crowd-backed beat probability while the other just shed 14% in a…
Apple is approaching another iPhone launch with a $4.5 trillion market cap and nearly two decades of stock gains that have crushed the broader market at every turn. The question now is whether that…
Four Dividend Aristocrats were flagged as stealth growth plays a year ago, and the results cut sharply in two directions. See which names delivered and which stumbled, plus three fresh picks where the dividend…
